Bowman-Birk inhibitors from legumes as colorectal chemopreventive agents

World Journal of Gastroenterology

Volumn 20, Issue 30, 2014, Pages 10305-10315

  Clemente, Alfonso ^a   Del Carmen Arques, Maria ^a  

^a CSIC   (Spain)

Author keywords

Bowman Birk inhibitors; Cell proliferation; Chemoprevention; Colorectal cancer; Legumes; Serine proteases

Indexed keywords

BOWMAN BIRK INHIBITOR; CHYMOTRYPSIN; SERINE PROTEINASE; TRYPSIN; ANTINEOPLASTIC AGENT; SERINE PROTEINASE INHIBITOR;

ARTICLE; CANCER INHIBITION; CANCER PREVENTION; CANCER STAGING; CHICKPEA; COLON CARCINOGENESIS; COLORECTAL CANCER; DIGESTION; DRUG TARGETING; GASTROINTESTINAL TRACT; HUMAN; LARGE INTESTINE; LEGUME; LENTIL; NONHUMAN; PEA; PROTEIN DEGRADATION; PROTEIN FAMILY; PROTEINASE INHIBITION; SOYBEAN; ANIMAL; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG DESIGN; ENZYMOLOGY; FABACEAE; ISOLATION AND PURIFICATION; MEDICINAL PLANT; METABOLISM; MOLECULARLY TARGETED THERAPY; PHYTOTHERAPY;

ANIMALS; ANTICARCINOGENIC AGENTS; COLORECTAL NEOPLASMS; DRUG DESIGN; FABACEAE; HUMANS; MOLECULAR TARGETED THERAPY; PHYTOTHERAPY; PLANTS, MEDICINAL; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; TRYPSIN INHIBITOR, BOWMAN-BIRK SOYBEAN;

EID: 84920624556     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i30.10305     Document Type: Article

References (96)

1. Turk B. Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov 2006; 5: 785-799 [PMID: 16955069 DOI: 10.1038/nrd2092]
2. Soreide K, Janssen EA, Körner H, Baak JP. Trypsin in colorectal cancer: molecular biological mechanisms of proliferation, invasion, and metastasis. J Pathol 2006; 209: 147-156 [PMID: 16691544 DOI: 10.1002/path.1999]
3. Sharony R, Yu PJ, Park J, Galloway AC, Mignatti P, Pintucci G. Protein targets of inflammatory serine proteases and cardiovascular disease. J Inflamm (Lond) 2010; 7: 45 [PMID: 20804552 DOI: 10.1186/1476-9255-7-45]
4. Safavi F, Rostami A. Role of serine proteases in inflammation: Bowman-Birk protease inhibitor (BBI) as a potential therapy for autoimmune diseases. Exp Mol Pathol 2012; 93: 428-433 [PMID: 23022357 DOI: 10.1016/j.yexmp.2012.09.014]
5. Deu E, Verdoes M, Bogyo M. New approaches for dissecting protease functions to improve probe development and drug discovery. Nat Struct Mol Biol 2012; 19: 9-16 [PMID: 22218294 DOI: 10.1038/nsmb.2203]
6. Clemente A, Domoney C, Therapeutic properties of legume protease inhibitors from the Bowman birk class. In: Govil JN, Singh VK, Sharma RK, editors. Recent Progress in Medicinal Plants. Houston: Studium Press, 2007: 345-365
7. Oliva ML, Ferreira Rda S, Ferreira JG, de Paula CA, Salas CE, Sampaio MU. Structural and functional properties of Kunitz proteinase inhibitors from Leguminosae: a mini review. Curr Protein Pept Sci 2011; 12: 348-357 [PMID: 21418019 DOI: 10.2174/138920311796391061]
8. Malkowicz SB, McKenna WG, Vaughn DJ, Wan XS, Propert KJ, Rockwell K, Marks SH, Wein AJ, Kennedy AR. Effects of Bowman-Birk inhibitor concentrate (BBIC) in patients with benign prostatic hyperplasia. Prostate 2001; 48: 16-28 [PMID: 11391683 DOI: 10.1002/pros.1077]
9. Armstrong WB, Kennedy AR, Wan XS, Atiba J, McLaren CE, Meyskens FL. Single-dose administration of Bowman-Birk inhibitor concentrate in patients with oral leukoplakia. Cancer Epidemiol Biomarkers Prev 2000; 9: 43-47 [PMID: 10667462]
10. Armstrong WB, Kennedy AR, Wan XS, Taylor TH, Nguyen QA, Jensen J, Thompson W, Lagerberg W, Meyskens FL. Clinical modulation of oral leukoplakia and protease activity by Bowman-Birk inhibitor concentrate in a phase IIa chemoprevention trial. Clin Cancer Res 2000; 6: 4684-4691 [PMID: 11156220]
11. Meyskens FL, Taylor T, Armstrong W, Kong L, Gu M, Gonzalez R, Villa M, Wong V, Garcia A, Perloff M, Kennedy A, Wan S, Ware JH, Messadi D, Lorch J, Wirth L, Jaffe Z, Goodwin J, Civantos F, Sullivan M, Reid M, Merciznu M, Jayaprakash V, Kerr AR, Le A. Phase IIb randomized clinical chemoprevention trial of a soybean-derived compound (Bowman-Birk inhibitor concentrate) for oral leukoplakia. Cancer Prev Res 2010; 3: CN02-05 [DOI: 10.1158/1940-6207. PREV-10-CN02-05]
12. Armstrong WB, Taylor TH, Kennedy AR, Melrose RJ, Messadi DV, Gu M, Le AD, Perloff M, Civantos F, Goodwin WJ, Wirth LJ, Kerr AR, Meyskens FL. Bowman birk inhibitor concentrate and oral leukoplakia: a randomized phase IIb trial. Cancer Prev Res (Phila) 2013; 6: 410-418 [PMID: 23639862 DOI: 10.1158/1940-6207.CAPR-13-0004]
13. Lichtenstein GR, Deren JJ, Katz S, Lewis JD, Kennedy AR, Ware JH. Bowman-Birk inhibitor concentrate: a novel therapeutic agent for patients with active ulcerative colitis. Dig Dis Sci 2008; 53: 175-180 [PMID: 17551835 DOI: 10.1007/s10620-007-9840-2]
14. Clemente A, Marín-Manzano MC, Arques MC, Domoney C. Bowman-Birk inhibitors from legumes: utilisation in disease prevention and therapy. In: Hernández-Ledesma B, Hsieh CC, editors. Bioactive food peptides in health and disease. Rijeka (Croatia): InTech-Open Access Publisher, 2013: 23-44
15. Chen P, Rose J, Love R, Wei CH, Wang BC. Reactive sites of an anticarcinogenic Bowman-Birk proteinase inhibitor are similar to other trypsin inhibitors. J Biol Chem 1992; 267: 1990-1994 [PMID: 1730730]
16. Bode W, Huber R. Natural protein proteinase inhibitors and their interaction with proteinases. Eur J Biochem 1992; 204: 433-451 [PMID: 1541261 DOI: 10.1111/j.1432-1033.1992. tb16654.x]
17. Li de la Sierra I, Quillien L, Flecker P, Gueguen J, Brunie S. Dimeric crystal structure of a Bowman-Birk protease inhibitor from pea seeds. J Mol Biol 1999; 285: 1195-1207 [PMID: 9887273 DOI: 10.1006/jmbi.1998.2351]
18. Schechter I, Berger A. On the size of the active site in proteases. I. Papain. 1967. Biochem Biophys Res Commun 2012; 425: 497-502 [PMID: 22925665 DOI: 10.1016/j.bbrc.2012.08.015]
19. Koepke J, Ermler U, Warkentin E, Wenzl G, Flecker P. Crystal structure of cancer chemopreventive Bowman-Birk inhibitor in ternary complex with bovine trypsin at 2.3 A resolution. Structural basis of Janus-faced serine protease inhibitor specificity. J Mol Biol 2000; 298: 477-491 [PMID: 10772864 DOI: 10.1006/jmbi.2000.3677]
20. Deshimaru M, Hanamoto R, Kusano C, Yoshimi S, Terada S. Purification and characterization of proteinase inhibitors from wild soja (Glycine soja) seeds. Biosci Biotechnol Biochem 2002; 66: 1897-1903 [PMID: 12400689 DOI: 10.1271/bbb.66.1897]
21. De Paola D, Blanco E, Pierri CL, Sonnante G. Isolation and characterization of novel variants of BBI coding genes from the legume Lathyrus sativus. Plant Physiol Biochem 2012; 57: 45-53 [PMID: 22677449 DOI: 10.1016/j.plaphy.2012.05.001]
22. Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995; 4: 337-360 [PMID: 7795518 DOI: 10.1002/pro.5560040301]
23. Lu W, Apostol I, Qasim MA, Warne N, Wynn R, Zhang WL, Anderson S, Chiang YW, Ogin E, Rothberg I, Ryan K, Laskowski M. Binding of amino acid side-chains to S1 cavities of serine proteinases. J Mol Biol 1997; 266: 441-461 [PMID: 9047374 DOI: 10.1006/jmbi.1996.0781]
24. Gariani T, Leatherbarrow RJ. Stability of protease inhibitors based on the Bowman-Birk reactive site loop to hydrolysis by proteases. J Pept Res 1997; 49: 467-475 [PMID: 9266473 DOI: 10.1111/j.1399-3011.1997.tb01153.x]
25. Gariani T, McBride JD, Leatherbarrow RJ. The role of the P2' position of Bowman-Birk proteinase inhibitor in the inhibition of trypsin. Studies on P2' variation in cyclic peptides encompassing the reactive site loop. Biochim Biophys Acta 1999; 1431: 232-237 [PMID: 10209295 DOI: 10.1016/S0167-4838(99)00035-7]
26. Clemente A, Moreno FJ, Marín-Manzano MC, Jiménez E, Domoney C. The cytotoxic effect of Bowman-Birk isoinhibitors, IBB1 and IBBD2, from soybean (Glycine max) on HT29 human colorectal cancer cells is related to their intrinsic ability to inhibit serine proteases. Mol Nutr Food Res 2010; 54: 396-405 [PMID: 19885848 DOI: 10.1002/mnfr.200900122]
27. Ferrasson E, Quillien L, Gueguen J. Proteinase inhibitors from pea seeds: purification and characterization. J Agric Food Chem 1997; 45: 127-131 [DOI: 10.1021/jf9603442]
28. Clemente A, MacKenzie DA, Jeenes DJ, Domoney C. The effect of variation within inhibitory domains on the activity of pea protease inhibitors from the Bowman-Birk class. Protein Expr Purif 2004; 36: 106-114 [PMID: 15177291 DOI: 10.1016/j.pep.2004.03.015]
29. Ragg EM, Galbusera V, Scarafoni A, Negri A, Tedeschi G, Consonni A, Sessa F, Duranti M. Inhibitory properties and solution structure of a potent Bowman-Birk protease inhibitor from lentil (Lens culinaris, L) seeds. FEBS J 2006; 273: 4024-4039 [PMID: 16889634 DOI: 10.1111/j.1742-4658.2006.05406.x]
30. Caccialupi P, Ceci LR, Siciliano RA, Pignone D, Clemente A, Sonnante G. Bowman-Birk inhibitors in lentil: heterologous expression, functional characterization and anti-proliferative properties in human colon cancer cells. Food Chem 2010; 120: 1058-1066 [DOI: 10.1016/j.foodchem.2009.11.051]
31. Scarafoni A, Consonni A, Galbusera V, Negri A, Tedeschi G, Rasmussen P, Magni C, Duranti M. Identification and characterization of a Bowman-Birk inhibitor active towards trypsin but not chymotrypsin in Lupinus albus seeds. Phytochemistry 2008; 69: 1820-1825 [PMID: 18474386 DOI: 10.1016/j.phytochem.2008.03.023]
32. Domoney C, Welham T, Ellis N, Mozzanega P, Turner L. Three classes of proteinase inhibitor gene have distinct but overlapping patterns of expression in Pisum sativum plants. Plant Mol Biol 2002; 48: 319-329 [PMID: 11855733 DOI: 10.1023/A:1013379430582]
33. Clemente A, Domoney C. Biological significance of polymorphism in legume protease inhibitors from the Bowman-Birk family. Curr Protein Pept Sci 2006; 7: 201-216 [PMID: 16787260 DOI: 10.2174/138920306777452349]
34. Quillien L, Ferrasson E, Molle D, Gueguen J. Trypsin inhibitor polymorphism: multigene family expression and posttranslational modification. J Protein Chem 1997; 16: 195-203 [PMID: 9155090 DOI: 10.1023/A:1026326808553]
35. Ramasarma PR, Rao AG, Rao DR. Role of disulfide linkages in structure and activity of proteinase inhibitor from horsegram (Dolichos biflorus). Biochim Biophys Acta 1995; 1248: 35-42 [PMID: 7711055 DOI: 10.1016/0167-4838(95)00004-E]
36. Singh RR, Appu Rao AG. Reductive unfolding and oxidative refolding of a Bowman-Birk inhibitor from horsegram seeds (Dolichos biflorus): evidence for "hyperreactive" disulfide bonds and rate-limiting nature of disulfide isomerization in folding. Biochim Biophys Acta 2002; 1597: 280-291 [PMID: 12044906 DOI: 10.1016/S0167-4838(02)00301-1]
37. Philipp S, Kim YM, Dürr I, Wenzl G, Vogt M, Flecker P. Mutational analysis of disulfide bonds in the trypsin-reactive subdomain of a Bowman-Birk-type inhibitor of trypsin and chymotrypsin-cooperative versus autonomous refolding of subdomains. Eur J Biochem 1998; 251: 854-862 [PMID: 9490061 DOI: 10.1046/j.1432-1327.1998.2510854.x]
38. Kumar V, Gowda LR. The contribution of two disulfide bonds in the trypsin binding domain of horsegram (Dolichos biflorus) Bowman-Birk inhibitor to thermal stability and functionality. Arch Biochem Biophys 2013; 537: 49-61 [PMID: 23791628 DOI: 10.1016/j.abb.2013.06.002]
39. Clemente A, Sonnante G, Domoney C. Bowman-Birk inhibitors from legumes and human gastrointestinal health: current status and perspectives. Curr Protein Pept Sci 2011; 12: 358-373 [PMID: 21418025 DOI: 10.2174/138920311796391 133]
40. Muricken DG, Gowda LR. Functional expression of horsegram (Dolichos biflorus) Bowman-Birk inhibitor and its self-association. Biochim Biophys Acta 2010; 1804: 1413-1423 [PMID: 20227530 DOI: 10.1016/j.bbapap.2010.02.012]
41. Park JH, Jeong HJ, Lumen BO. In vitro digestibility of the cancer-preventive soy peptides lunasin and BBI. J Agric Food Chem 2007; 55: 10703-10706 [PMID: 18038984 DOI: 10.1021/jf072107c]
42. Weder JK. Inhibition of human proteinases by grain legumes. Adv Exp Med Biol 1986; 199: 239-279 [PMID: 3799279 DOI: 10.1007/978-1-4757-0022-0-16]
43. Trivedi MV, Laurence JS, Siahaan TJ. The role of thiols and disulfides on protein stability. Curr Protein Pept Sci 2009; 10: 614-625 [PMID: 19538140 DOI: 10.2174/138920309789630534]
44. Bateman KS, James MN. Plant protein proteinase inhibitors: structure and mechanism of inhibition. Curr Protein Pept Sci 2011; 12: 340-347 [PMID: 21418022 DOI: 10.2174/1389203117 96391124]
45. Hajós G, Gelencsér E, Pusztai A, Grant G, Sakhri M, Bardocz S. Biological effects and survival of trypsin inhibitors and the agglutinin from soybean in the small intestine of the rat. J Agric Food Chem 1995; 43: 165-170 [DOI: 10.1021/jf00049a030]
46. Pusztai A, Grant G, Brown DJ, Stewart JC, Bardocz S, Ewen SW, Gatehouse AM, Hilder V. Nutritional evaluation of the trypsin (EC 3.4.21.4) inhibitor from cowpea (Vigna unguiculata Walp.). Br J Nutr 1992; 68: 783-791 [PMID: 1493140]
47. Clemente A, Jiménez E, Marín-Manzano MC, Rubio LA. Active Bowman-Birk inhibitors survive gastrointestinal digestion at the terminal ileum of pigs fed chickpea-based diets. J Sci Food Agric 2008; 88: 523-531 [DOI: 10.1002/jsfa.3115]
48. Marín-Manzano MC, Ruiz R, Jiménez E, Rubio LA, Clemente A. Anti-carcinogenic soyabean Bowman-Birk inhibitors survive faecal fermentation in their active form and do not affect the microbiota composition in vitro. Br J Nutr 2009; 101: 967-971 [PMID: 19353764 DOI: 10.1017/S0007114508057590]
49. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90 [PMID: 21296855 DOI: 10.3322/caac.20107]
50. Aune D, De Stefani E, Ronco A, Boffetta P, Deneo-Pellegrini H, Acosta G, Mendilaharsu M. Legume intake and the risk of cancer: a multisite case-control study in Uruguay. Cancer Causes Control 2009; 20: 1605-1615 [PMID: 19653110 DOI: 10.1007/s10552-009-9406-z]
51. Wang Y, Wang Z, Fu L, Chen Y, Fang J. Legume consumption and colorectal adenoma risk: a meta-analysis of observational studies. PLoS One 2013; 8: e67335 [PMID: 23826270 DOI: 10.1371/journal.pone.0067335]
52. Kennedy AR, Billings PC, Wan XS, Newberne PM. Effects of Bowman-Birk inhibitor on rat colon carcinogenesis. Nutr Cancer 2002; 43: 174-186 [PMID: 12588698 DOI: 10.1207/S15327914NC432-8]
53. St Clair WH, Billings PC, Carew JA, Keller-McGandy C, Newberne P, Kennedy AR. Suppression of dimethylhydra-zine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res 1990; 50: 580-586 [PMID: 2297699]
54. Clemente A, Gee JM, Johnson IT, Mackenzie DA, Domoney C. Pea (Pisum sativum L.) protease inhibitors from the Bowman-Birk class influence the growth of human colorectal adenocarcinoma HT29 cells in vitro. J Agric Food Chem 2005; 53: 8979-8986 [PMID: 16277391 DOI: 10.1021/jf051528w]
55. Clemente A, Carmen Marín-Manzano M, Jiménez E, Carmen Arques M, Domoney C. The anti-proliferative effect of TI1B, a major Bowman-Birk isoinhibitor from pea (Pisum sativum L.), on HT29 colon cancer cells is mediated through protease inhibition. Br J Nutr 2012; 108 Suppl 1: S135-S144 [PMID: 22916809 DOI: 10.1017/S000711451200075X]
56. Yavelow J, Collins M, Birk Y, Troll W, Kennedy AR. Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray-induced transformation in vitro. Proc Natl Acad Sci USA 1985; 82: 5395-5399 [PMID: 3860869 DOI: 10.1073/pnas.82.16.5395]
57. Billings PC, Newberne PM, Kennedy AR. Protease inhibitor suppression of colon and anal gland carcinogenesis induced by dimethylhydrazine. Carcinogenesis 1990; 11: 1083-1086 [PMID: 2372868 DOI: 10.1093/carcin/11.7.1083]
58. Ware JH, Wan XS, Newberne P, Kennedy AR. Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis. Dig Dis Sci 1999; 44: 986-990 [PMID: 10235608 DOI: 10.1023/A:1026616832119]
59. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 1987; 92: 1894-1898 [PMID: 3569765]
60. Frenkel K, Chrzan K, Ryan CA, Wiesner R, Troll W. Chymotrypsin-specific protease inhibitors decrease H2O2 formation by activated human polymorphonuclear leukocytes. Carcinogenesis 1987; 8: 1207-1212 [PMID: 3621459 DOI: 10.1093/carcin/8.9.1207]
61. Ware JH, Wan XS, Kennedy AR. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells. Nutr Cancer 1999; 33: 174-177 [PMID: 10368813 DOI: 10.1207/S15327914NC330209]
62. Baturay NZ, Roque H. In vitro reduction of peroxidation in UVC-irradiated cell cultures by concurrent exposure with Bowman-Birk protease inhibitor. Teratog Carcinog Mutagen 1991; 11: 195-202 [PMID: 1685807 DOI: 10.1002/tcm.1770110404]
63. Shimoda N, Fukazawa N, Nonomura K, Fairchild RL. Cathepsin G is required for sustained inflammation and tissue injury after reperfusion of ischemic kidneys. Am J Pathol 2007; 170: 930-940 [PMID: 17322378 DOI: 10.2353/ajpath.2007.060486]
64. Annaházi A, Gecse K, Dabek M, Ait-Belgnaoui A, Rosztóczy A, Róka R, Molnár T, Theodorou V, Wittmann T, Bueno L, Eutamene H. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 2009; 144: 209-217 [PMID: 19450926 DOI: 10.1016/j.pain.2009.04.017]
65. Yoshida N, Isozaki Y, Takagi T, Takenaka S, Uchikawa R, Arizono N, Yoshikawa T, Okanoue T. Anti-tryptase therapy in inflammatory bowel disease. Aliment Pharmacol Ther Symp Ser 2006; 2: 249-255 [DOI: 10.1111/j.1365-2036.2006.00053.x]
66. Róka R, Rosztóczy A, Leveque M, Izbéki F, Nagy F, Molnár T, Lonovics J, Garcia-Villar R, Fioramonti J, Wittmann T, Bueno L. A pilot study of fecal serine-protease activity: a pathophysiologic factor in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol 2007; 5: 550-555 [PMID: 17336590 DOI: 10.1016/j.cgh.2006.12.004]
67. Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-599 [PMID: 18194983 DOI: 10.1136/gut.2007.140210]
68. Hawkins JV, Emmel EL, Feuer JJ, Nedelman MA, Harvey CJ, Klein HJ, Rozmiarek H, Kennedy AR, Lichtenstein GR, Billings PC. Protease activity in a hapten-induced model of ulcerative colitis in rats. Dig Dis Sci 1997; 42: 1969-1980 [PMID: 9331164 DOI: 10.1023/A:1018887832465]
69. Weldon S, McNally P, McElvaney NG, Elborn JS, McAuley DF, Wartelle J, Belaaouaj A, Levine RL, Taggart CC. Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol 2009; 183: 8148-8156 [PMID: 20007580 DOI: 10.4049/jimmunol.0901716]
70. Inoue Y, Yokobori T, Yokoe T, Toiyama Y, Miki C, Mimori K, Mori M, Kusunoki M. Clinical significance of human kallikrein7 gene expression in colorectal cancer. Ann Surg Oncol 2010; 17: 3037-3042 [PMID: 20544292 DOI: 10.1245/s10434-010-1132-y]
71. Petraki C, Dubinski W, Scorilas A, Saleh C, Pasic MD, Komborozos V, Khalil B, Gabril MY, Streutker C, Diamandis EP, Yousef GM. Evaluation and prognostic significance of human tissue kallikrein-related peptidase 6 (KLK6) in colorectal cancer. Pathol Res Pract 2012; 208: 104-108 [PMID: 22285222 DOI: 10.1016/j.prp.2011.12.010]
72. Scott CJ, Taggart CC. Biologic protease inhibitors as novel therapeutic agents. Biochimie 2010; 92: 1681-1688 [PMID: 20346385 DOI: 10.1016/j.biochi.2010.03.010]
73. Latonen L, Moore HM, Bai B, Jäämaa S, Laiho M. Proteasome inhibitors induce nucleolar aggregation of proteasome target proteins and polyadenylated RNA by altering ubiquitin availability. Oncogene 2011; 30: 790-805 [PMID: 20956947 DOI: 10.1038/onc.2010.469]
74. Kisselev AF, Callard A, Goldberg AL. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate. J Biol Chem 2006; 281: 8582-8590 [PMID: 16455650 DOI: 10.1074/jbc. M509043200]
75. Wu WK, Cho CH, Lee CW, Wu K, Fan D, Yu J, Sung JJ. Proteasome inhibition: a new therapeutic strategy to cancer treatment. Cancer Lett 2010; 293: 15-22 [PMID: 20133049 DOI: 10.1016/j.canlet.2009.12.002]
76. Chen YW, Huang SC, Lin-Shiau SY, Lin JK. Bowman-Birk inhibitor abates proteasome function and suppresses the proliferation of MCF7 breast cancer cells through accumulation of MAP kinase phosphatase-1. Carcinogenesis 2005; 26: 1296-1306 [PMID: 15746161 DOI: 10.1093/carcin/bgi062]
77. Billings PC, Brandon DL, Habres JM. Internalisation of the Bowman-Birk protease inhibitor by intestinal epithelial cells. Eur J Cancer 1991; 27: 903-908 [PMID: 1834126 DOI: 10.1016/0277-5379(91)90144-3]
78. Souza Lda C, Camargo R, Demasi M, Santana JM, de Sá CM, de Freitas SM. Effects of an anticarcinogenic Bowman-Birk protease inhibitor on purified 20S proteasome and MCF-7 breast cancer cells. PLoS One 2014; 9: e86600 [PMID: 24475156 DOI: 10.1371/journal.pone.0086600]
79. de Paula Carli A, de Abreu Vieira PM, Silva KT, de Sá Cota RG, Carneiro CM, Castro-Borges W, de Andrade MH. Bowman-Birk inhibitors, proteasome peptidase activities and colorectal pre neoplasias induced by 1, 2-dimethylhydrazine in Swiss mice. Food Chem Toxicol 2012; 50: 1405-1412 [PMID: 22326805 DOI: 10.1016/j.fct.2012.01.036]
80. Saito T, Sato H, Virgona N, Hagiwara H, Kashiwagi K, Suzuki K, Asano R, Yano T. Negative growth control of osteosarcoma cell by Bowman-Birk protease inhibitor from soybean; involvement of connexin 43. Cancer Lett 2007; 253: 249-257 [PMID: 17343982 DOI: 10.1016/j.canlet.2007.01.021]
81. Bhatt AS, Takeuchi T, Ylstra B, Ginzinger D, Albertson D, Shuman MA, Craik CS. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem 2003; 384: 257-266 [PMID: 12675519 DOI: 10.1515/BC.2003.029]
82. Bugge TH, Antalis TM, Wu Q. Type II transmembrane serine proteases. J Biol Chem 2009; 284: 23177-23181 [PMID: 19487698 DOI: 10.1074/jbc.R109.021006]
83. Lee SL, Dickson RB, Lin CY. Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease. J Biol Chem 2000; 275: 36720-36725 [PMID: 10962009 DOI: 10.1074/jbc. M007802200]
84. List K, Kosa P, Szabo R, Bey AL, Wang CB, Molinolo A, Bugge TH. Epithelial integrity is maintained by a matriptasedependent proteolytic pathway. Am J Pathol 2009; 175: 1453-1463 [PMID: 19717635 DOI: 10.2353/ajpath.2009.090240]
85. Long YQ, Lee SL, Lin CY, Enyedy IJ, Wang S, Li P, Dickson RB, Roller PP. Synthesis and evaluation of the sunflower derived trypsin inhibitor as a potent inhibitor of the type II transmembrane serine protease, matriptase. Bioorg Med Chem Lett 2001; 11: 2515-2519 [PMID: 11549459 DOI: 10.1016/S0960-894X(01)00493-0]
86. Yamasaki Y, Satomi S, Murai N, Tsuzuki S, Fushiki T. Inhibition of membrane-type serine protease 1/matriptase by natural and synthetic protease inhibitors. J Nutr Sci Vitaminol (Tokyo) 2003; 49: 27-32 [PMID: 12882393]
87. Larionova NI, Gladysheva IP, Tikhonova TV, Kazanskaia NF. [Inhibition of cathepsin G and elastase from human granulocytes by multiple forms of the Bowman-Birk type of soy inhibitor]. Biokhimiia 1993; 58: 1437-1444 [PMID: 8218567]
88. Gladysheva IP, Zamolodchikova TS, Sokolova EA, Larionova NI. Interaction between duodenase, a proteinase with dual specificity, and soybean inhibitors of Bowman-Birk and Kunitz type. Biochemistry (Mosc) 1999; 64: 1244-1249 [PMID: 10611528 DOI: 10.1023/A:1010267500296]
89. Ware JH, Wan XS, Rubin H, Schechter NM, Kennedy AR. Soybean Bowman-Birk protease inhibitor is a highly effective inhibitor of human mast cell chymase. Arch Biochem Biophys 1997; 344: 133-138 [PMID: 9244390 DOI: 10.1006/abbi.1997.0182]
90. Tani K, Ogushi F, Kido H, Kawano T, Kunori Y, Kamimura T, Cui P, Sone S. Chymase is a potent chemoattractant for human monocytes and neutrophils. J Leukoc Biol 2000; 67: 585-589 [PMID: 10770293]
91. Saarinen J, Kalkkinen N, Welgus HG, Kovanen PT. Activation of human interstitial procollagenase through direct cleavage of the Leu83-Thr84 bond by mast cell chymase. J Biol Chem 1994; 269: 18134-18140 [PMID: 8027075]
92. Mizutani H, Schechter N, Lazarus G, Black RA, Kupper TS. Rapid and specific conversion of precursor interleukin 1 beta (IL-1 beta) to an active IL-1 species by human mast cell chymase. J Exp Med 1991; 174: 821-825 [PMID: 1919436]
93. Fernandes AO, Banerji AP. Inhibition of benzopyrene-induced forestomach tumors by field bean protease inhibitor(s). Carcinogenesis 1995; 16: 1843-1846 [PMID: 7634412 DOI: 10.1093/carcin/16.8.1843]
94. Fukusen N, Kato Y, Kido H, Katunuma N. Kinetic studies on the inhibitions of mast cell chymase by natural serine protease inhibitors: indications for potential biological functions of these inhibitors. Biochem Med Metab Biol 1987; 38: 165-169 [PMID: 3479119 DOI: 10.1016/0885-4505(87)90076-4]
95. Tikhonova TV, Gladysheva IP, Larionova NI. Retardation by the soybean Bowman-Birk inhibitor of elastin hydrolysis catalyzed by leukocyte proteinases. FEBS Lett 1995; 362: 225-228 [PMID: 7720877 DOI: 10.1016/0014-5793(95)00202-K]
96. Larionova NI, Gladysheva IP, Gladyshev DP. Human leukocyte elastase inhibition by Bowman-Birk soybean inhibitor. Discrimination of the inhibition mechanisms. FEBS Lett 1997; 404: 245-248 [PMID: 9119072 DOI: 10.1016/S0014-5793(97)00089-6]